


## ATR-IN-23

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-149952   |
| <b>CAS No.:</b>           | 2923800-62-6  |
| <b>Molecular Formula:</b> | C <sub>20</sub> H <sub>22</sub> N <sub>6</sub> O <sub>3</sub> S <sub>2</sub>              |
| <b>Molecular Weight:</b>  | 458.56  |
| <b>Target:</b>            | ATM/ATR   |
| <b>Pathway:</b>           | Cell Cycle/DNA Damage; PI3K/Akt/mTOR  |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                        |  |
|------------------------|--|
| <b>Description</b>     | ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC <sub>50</sub> of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers <sup>[1]</sup> .  |
| <b>In Vitro</b>        | ATR-IN-23 possesses significant inhibitory potency against ATR, with an IC <sub>50</sub> value of 1.5 nM, and displays strong antiproliferative activities against LoVo cells, with an IC <sub>50</sub> value of 0.073 μM <sup>[1]</sup> .<br>ATR-IN-23 exhibits moderate antiproliferative potency against HT-29 cells with an IC <sub>50</sub> value of 0.161 μM <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| <b>In Vivo</b>         | ATR-IN-23 shows acute toxicity at a maximum concentration of 2000 mg/kg and possesses moderate safety in ICR mice <sup>[1]</sup> .<br>ATR-IN-23 (50 mg/kg; once a day or twice a day; p.o.; 21 days) exhibits moderate antitumor efficacy in BALB/c nude mice <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |
| <b>Animal Model:</b>   | BALB/c nude mice <sup>[1]</sup>  |
| <b>Dosage:</b>         | 50 mg/kg   |
| <b>Administration:</b> | p.o., once a day or twice a day for 21 consecutive days, dissolved in a solution of DMSO (10%), solutol (10%), and saline (80%)  |
| <b>Result:</b>         | Exhibited moderate antitumor efficacy, with a tumor growth inhibition (TGI) value of 55% at dosages of 50 mg/kg twice a day.   |

### REFERENCES

[1]. Duan Y, et al. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase. *Eur J Med Chem.* 2023 Jul 5;255:115370.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA